Cytokinetics director Daly granted 197 share retainer

Cytokinetics director James M. Daly reported receiving company stock as board compensation.

Rhea-AI Filing Summary

Cytokinetics director James M. Daly reported receiving company stock as board compensation. On January 15, 2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. These fully vested shares were received in lieu of a cash retainer under an equity-in-lieu-of-cash option available to members of the board of directors. Following this transaction, Daly beneficially owned 197 shares of Cytokinetics common stock in direct ownership.

Insider Trade Summary

Grant/Award: 197 shares

Grant/Award 1 txn

Insider Daly James M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	197	$63.44	$12K

Holdings After Transaction: Common Stock — 197 shares (Direct)

Footnotes (1)

1. F1. Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of Issuer's Board of Directors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cytokinetics (CYTK) report for James M. Daly?

James M. Daly, a director of Cytokinetics, reported acquiring 197 shares of Cytokinetics common stock on January 15, 2026. The transaction was coded as an acquisition of non-derivative securities.

At what price did James M. Daly acquire Cytokinetics (CYTK) shares?

Daly acquired 197 shares of Cytokinetics common stock at a price of $63.44 per share, as disclosed in the Form 4 filing.

Why did James M. Daly receive Cytokinetics (CYTK) shares instead of cash?

According to the footnote, Daly received fully vested shares of common stock in lieu of a cash retainer, under an Equity in Lieu of Cash Retainer Option available to members of Cytokinetics' board of directors.

How many Cytokinetics (CYTK) shares does James M. Daly own after this transaction?

Following the reported transaction, Daly beneficially owned 197 shares of Cytokinetics common stock in direct ownership, as stated in the Form 4.

Is the James M. Daly Form 4 transaction at Cytokinetics (CYTK) a purchase on the open market?

No. The filing states that Daly received fully vested shares as equity compensation in lieu of a cash retainer for board service, rather than buying shares on the open market.

What type of security did James M. Daly receive from Cytokinetics (CYTK)?

Daly received common stock of Cytokinetics, reported in Table I for non-derivative securities, with no derivative securities reported in Table II.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/20/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly James M

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		A(1)		197	A	$63.44	197	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Fully vested shares of common stock received in lieu of cash retainer pursuant to Equity in Lieu of Cash Retainer Option available to members of Issuer's Board of Directors.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Daly	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.